Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
ESTRADERM |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estradiol 0.05mg/day, 0.1mg/day; transdermal patch. |
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Atrophic vaginitis. Hypoestrogenism. Osteoporosis prevention. |
| Children |
|
Not applicable. |
| Adults |
|
Initially one 0.05mg/day patch twice per week applied to trunk (avoid breasts, waistline). Maintenance: administer cyclically (3 weeks on, 1 week off). Rotate application sites. Reevaluate periodically. Osteoporosis: supplement diet with calcium 1–1.5 g/day. |
| Contraindications |
|
Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Breast or estrogen-dependent carcinoma. Pregnancy (Cat.X). |
| Precautions |
|
Family history of breast cancer. Coronary artery or cerebrovascular disease. Hepatic dysfunction. Conditions aggravated by fluid retention. Endometriosis. Gallbladder disease. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include BP, mammogram, and PAP smear). Discontinue if hypercalcemia or jaundice occurs. Nursing mothers. |
| Adverse Reactions |
|
See literature. Increased risk of endometrial cancer or hyperplasia, gallbladder disease. Local irritation, fluid retention, breakthrough bleeding, weight or menstrual changes, mastodynia, nausea, abdominal cramps, headache, migraine, dizziness, intolerance to contact lenses. |
| How Supplied |
|
Patch—8, 24 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
